- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.08. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Medicus Pharma Ltd. reports Q2 results | 1 | Seeking Alpha | ||
| 21.08. | Medicus Pharma erzielt Fortschritte bei Hautkrebsmittel vor FDA-Gespräch | 1 | Investing.com Deutsch | ||
| 21.08. | Medicus Pharma advances skin cancer treatment as FDA meeting approaches | 1 | Investing.com | ||
| 21.08. | Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights | 196 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development... ► Artikel lesen | |
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines | 250 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused... ► Artikel lesen | |
| 04.08. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders | 322 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and... ► Artikel lesen | |
| 21.07. | Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 | 285 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza... ► Artikel lesen | |
| 14.07. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA) | 286 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United... ► Artikel lesen | |
| 04.07. | Medicus Pharma: Pflaster gegen Hautkrebs - ein Investment wert? | 603 | sharedeals.de | Eine hierzulande wohl ziemlich unbekannte Aktie ist die von Medicus Pharma. Das Unternehmen aus Kanada ist seit Ende letzten Jahres auch an der US-Nasdaq gelistet und hat Großes vor. Wenn der Plan aufgeht... ► Artikel lesen | |
| 30.06. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 30.06. | Medicus Pharma to acquire Antev | 5 | Seeking Alpha | ||
| 30.06. | Medicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK | 366 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced... ► Artikel lesen | |
| 30.06. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | 172 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameCA58471K2020 MEDICUS PHARMA LTD.DE000HLB5782... ► Artikel lesen | |
| 23.06. | Medicus Pharma appoints Andrew Smith as chief operating officer | 2 | Investing.com | ||
| 23.06. | Medicus Pharma ernennt Andrew Smith zum Chief Operating Officer | 2 | Investing.com Deutsch |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,220 | +0,74 % | Pfizer Inc.: Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted... ► Artikel lesen | |
| GILEAD SCIENCES | 96,42 | +0,07 % | Gilead: Übernahme | Eine weitere Übernahme im Sektor: Die Biotech-Gesellschaft Gilead Sciences baut seine Entwicklungspipeline im Bereich der Onkologie weiter aus. Für einen dreistelligen Millionen-Dollar-Betrag wollen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 337,50 | +0,55 % | Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex | ||
| EYEPOINT PHARMACEUTICALS | 10,040 | +1,09 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ROCKET LAB | 40,000 | -2,91 % | Rocket Lab überrascht: Raketen gegen SpaceX - Depot-2030-Aktie hebt ab | Neue Fantasie: Die Raumfahrtfirma Rocket Lab investiert nun auch in weltraumtaugliche Solarzellen. Haupttreiber sind die schnell aufeinanderfolgenden Raketenstarts.Der Hot Stock Rocket Lab zündet und... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,750 | +2,68 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
| OPKO HEALTH | 1,202 | -0,81 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 137,00 | 0,00 % | Ligand Pharma stock price target raised to $206 from $157 at H.C. Wainwright | ||
| JAZZ PHARMACEUTICALS | 106,35 | -1,48 % | Jazz Pharmaceuticals stock price target raised to $205 by Truist Securities | ||
| UNITED THERAPEUTICS | 262,10 | -0,30 % | MannKind rises as United Therapeutics exercises option for second inhalational drug | ||
| ROYALTY PHARMA | 30,950 | +1,51 % | Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) has acquired a royalty interest in Amgen's Imdelltra, a DLL3 targeting bispecific T-cell engager, from BeOne Medicines for $885 million upfront.... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,695 | +1,40 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 44,480 | -1,18 % | BridgeBio Pharma, Inc.: BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 | ||
| TG THERAPEUTICS | 24,785 | 0,00 % | TG Therapeutics, Inc.: TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,300 | -2,92 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.